Puma Biotechnology Sees Q3 Sales $56.000M-$59.000M vs $60.500M Est

Benzinga Newsdesk www.benzinga.com Positive 78.4%

Neg 0% Neu 0% Pos 78.4%

Puma Biotechnology (NASDAQ:PBYI) sees Q3 sales of $56.000 million-$59.000 million vs $60.500 million analyst estimate.

Comments

No comments yet. Be the first!